Goal-Directed Therapy Following Cardiac Surgery

July 19, 2023 updated by: University of Calgary

Goal-Directed Therapy (GDT) Using Hypotension Prediction Index (HPI) Following Cardiac Surgery: a Pilot Randomized Control Trial

Pilot prospective randomized control trial comparing goal-directed therapy algorithm vs routine care in the intensive care unit following cardiac surgery.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

Rationale:

Goal-directed therapy (GDT) has been shown to reduce complications and length of stay on cardiac surgery patients. Unfortunately, the existing literature on GDT in CV surgery has several limitations, which creates uncertainty over the expected benefit of implementing this care element with high associated costs and impact on workflow. Hypotension Prediction Index (HPI) is a proprietary algorithm that utilizes pulse contour analysis from invasive arterial pressure monitoring to identify patients at risk for becoming hypotensive within 15 minutes. The algorithm was developed using machine learning on a large surgical/ICU data set, and then externally validated on non-cardiac and cardiac surgical patients. HPI, as part of a GDT algorithm, may allow healthcare providers to identify patients recovering from cardiac surgery who may benefit from optimization prior to becoming hypotensive and assist with selecting the most appropriate hemodynamic intervention.

Hypothesis:

Application of an HPI-based GDT algorithm will result in a difference in cumulative fluid administration over the first 24-hours of index ICU admission following cardiac surgery.

Study Design:

Unblinded randomized controlled trial pilot. Data will be used to inform/justify the feasibility, design, and implementation of a future multi-center randomized controlled trial.

Study Population:

Moderate or high-risk (EuroSCORE II > 2%), non-emergent, adult open-heart cardiac surgery patients. Heart transplant, durable VAD implantation, or patients who require post-operative MCS support will be excluded.

Sample size= 100 (50 control : 50 intervention)

Intervention:

Patients randomized to the intervention arm will be monitored using the HPI technology and be treated following a GDT algorithm when HPI is >50 for 48-hours or duration of invasive arterial monitoring (whichever occurs first). The GDT algorithm is a standardized approach to identifying abnormal hemodynamic parameters and administering a prescribed therapy in a step-wise fashion with fixed re-assessment intervals (see attached).

What will be different from routine care? :

  1. Hemodynamic interventions (fluid, inotropic, or vasopressor therapy) will be administered when HPI > 50 rather than MAP < 65.
  2. Choice of applied therapy (fluid, inotropic, or vasopressor therapy) will be guided by a GDT algorithm.

Study Type

Interventional

Enrollment (Estimated)

100

Phase

  • Not Applicable

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. ≥ 18 years of age
  2. Planned cardiac surgery using cardiopulmonary bypass (sternotomy or MICS)
  3. Preoperative European System for Cardiac Operative Risk Evaluation II (EuroSCORE II) of 2% or more.
  4. Informed consent obtained.

Exclusion Criteria:

  1. Patients who refuse participation
  2. Patients who are unable to give informed consent
  3. Patients who are having a heart transplant or having surgery solely for an insertion of a ventricular assist device
  4. Emergency surgery
  5. Patients who require MCS (including ECMO, Impella, or IABP) post-operatively

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
No Intervention: Control
Routine post-operative clinical care.
Experimental: Intervention
Goal-directed therapy algorithm in addition to routine post-operative clinical care.
Goal-directed therapy using HemoSphere® monitor, Acumen® transducer, and Hypotension Prediction Index® algorithm (Edwards Lifesciences, Irvine, USA),

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
24-hour cumulative IV fluid administration
Time Frame: 24-hours
Cumulative post-operative intravenous fluid administration over the first 24-hours of index ICU admission.
24-hours

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Fluid Administration
Time Frame: Duration of ICU stay, up to 30-days
Daily average
Duration of ICU stay, up to 30-days
Fluid Administration
Time Frame: Duration of ICU stay, up to 30-days
Cumulative
Duration of ICU stay, up to 30-days
Vasoactive medication administration
Time Frame: Duration of ICU stay, up to 30-days
Daily average
Duration of ICU stay, up to 30-days
Vasoactive medication administration
Time Frame: Duration of ICU stay, up to 30-days
Daily cumulative
Duration of ICU stay, up to 30-days
Vasoactive medication administration
Time Frame: Duration of ICU stay, up to 30-days
Duration
Duration of ICU stay, up to 30-days
Hemodynamic parameters
Time Frame: 48-hours or when arterial line removed
Incidence of HPI > 50 greater than 5-minutes
48-hours or when arterial line removed
Hemodynamic parameters
Time Frame: 48-hours or when arterial line removed
Incidence of HPI > 85 greater than 5-minutes
48-hours or when arterial line removed
Hemodynamic parameters
Time Frame: 48-hours or when arterial line removed
Incidence of MAP < 65 greater than 5-minutes
48-hours or when arterial line removed
Hemodynamic parameters
Time Frame: 24-hours
Total Area Under the Curve (AUC) for HPI > 50
24-hours
Hemodynamic parameters
Time Frame: 48-hours or when arterial line removed
Total Area Under the Curve (AUC) for HPI > 50
48-hours or when arterial line removed
Hemodynamic parameters
Time Frame: 24-hours
Total Area Under the Curve (AUC) for HPI > 85
24-hours
Hemodynamic parameters
Time Frame: 48-hours or when arterial line removed
Total Area Under the Curve (AUC) for HPI > 85
48-hours or when arterial line removed
Hemodynamic parameters
Time Frame: 24-hours
Total Area Under the Curve (AUC) for MAP < 65
24-hours
Hemodynamic parameters
Time Frame: 48-hours or when arterial line removed
Total Area Under the Curve (AUC) for MAP < 65
48-hours or when arterial line removed
Enrollment
Time Frame: 1-year
Proportion of screened patients eligible for enrollment.
1-year
Enrollment
Time Frame: 1-year
Proportion of eligible patients who consent to participate.
1-year
Study Protocol Compliance
Time Frame: 1-year
Proportion of consented patients who complete all study assessments.
1-year
Arterial Monitoring Reliability
Time Frame: 1-year
Number of arterial catheters requiring replacement
1-year
GDT algorithm compliance
Time Frame: 48-hours or when arterial line removed
Time from HPI > 50 to application of an intervention
48-hours or when arterial line removed
GDT algorithm compliance
Time Frame: 48-hours or when arterial line removed
Proportion of hemodynamic interventions applied for HPI > 50 that were recommended by the algorithm
48-hours or when arterial line removed
GDT algorithm compliance
Time Frame: 48-hours or when arterial line removed
Proportion of hemodynamic interventions applied for MAP < 65 that would be recommended by the algorithm based on hemodynamic parameters.
48-hours or when arterial line removed
GDT algorithm compliance
Time Frame: 48-hours or when arterial line removed
MD notifications prompted by the GDT algorithm and resulting actions
48-hours or when arterial line removed
GDT algorithm compliance
Time Frame: 48-hours or when arterial line removed
Actions (therapies or investigations) prompted by an MD notification.
48-hours or when arterial line removed
GDT algorithm compliance
Time Frame: 48-hours or when arterial line removed
Number of study protocol suspensions
48-hours or when arterial line removed
GDT algorithm compliance
Time Frame: 48-hours or when arterial line removed
Duration of protocol suspensions
48-hours or when arterial line removed
GDT algorithm compliance
Time Frame: 48-hours or when arterial line removed
Rationale for protocol suspensions
48-hours or when arterial line removed
End-organ dysfunction/injury
Time Frame: Index admission, up to 30-days
Acute kidney injury
Index admission, up to 30-days
End-organ dysfunction/injury
Time Frame: Index admission, up to 30-days
Delirium
Index admission, up to 30-days
End-organ dysfunction/injury
Time Frame: Index admission, up to 30-days
Stroke
Index admission, up to 30-days
End-organ dysfunction/injury
Time Frame: Index admission, up to 30-days
Ileus
Index admission, up to 30-days
End-organ dysfunction/injury
Time Frame: Index admission, up to 30-days
Gut infarction
Index admission, up to 30-days
End-organ dysfunction/injury
Time Frame: Index admission, up to 30-days
Prolonged mechanical ventilation (> 24 hours)
Index admission, up to 30-days
End-organ dysfunction/injury
Time Frame: Index admission, up to 30-days
Deep sternal wound infection
Index admission, up to 30-days
End-organ dysfunction/injury
Time Frame: Index admission, up to 30-days
Any surgical site infection
Index admission, up to 30-days
Transfusion
Time Frame: Index admission, up to 30-days
Total red-blood cell administration
Index admission, up to 30-days
Transfusion
Time Frame: Index admission, up to 30-days
Total fresh-frozen plasma administration
Index admission, up to 30-days
Transfusion
Time Frame: Index admission, up to 30-days
Total platelet administration
Index admission, up to 30-days
Transfusion
Time Frame: Index admission, up to 30-days
Total albumin administration
Index admission, up to 30-days
Mobilzation
Time Frame: Index admission, up to 30-days
Time to first mobilization (dangle)
Index admission, up to 30-days
Mobilzation
Time Frame: Index admission, up to 30-days
Time to first mobilization (stand)
Index admission, up to 30-days
Mobilization
Time Frame: Index admission, up to 30-days
Time to first mobilization (walk)
Index admission, up to 30-days
Hydration
Time Frame: Index admission, up to 30-days
Time to first PO hydration
Index admission, up to 30-days
Nutrition
Time Frame: Index admission, up to 30-days
Time to first PO nutrition
Index admission, up to 30-days
Patient-centered Outcome
Time Frame: Index admission, up to 10-days
Quality of Recovery-15 (QOR-15) at post-op days 3, 5, 7, and 10.
Index admission, up to 10-days
Patient-centered Outcome
Time Frame: Up to 1-year post-operative
World Health Organization Disability Assessment Schedule (WHODAS 2.0) at baseline, 2-weeks, 30-days, 90-days, and 1-year.
Up to 1-year post-operative
Patient-centered Outcome
Time Frame: Up to 1-year post-operative
MacNew Questionnaire at baseline, 2-weeks, 30-days, 90-days, and 1-year.
Up to 1-year post-operative
Patient-centered Outcome
Time Frame: Up to 1-year post-operative
The Depression, Anxiety and Stress Scale - 21 Items (DASS-21) at baseline, 2-weeks, 30-days, 90-days, and 1-year.
Up to 1-year post-operative
Patient-centered Outcome
Time Frame: 30-days
Canadian Patient Experiences Survey on Inpatient Care (CPES-IC) at 30-days
30-days
Length of Stay
Time Frame: Up to 1-year post-operative
ICU length of stay
Up to 1-year post-operative
Length of Stay
Time Frame: Up to 1-year post-operative
Hospital length of stay
Up to 1-year post-operative
Re-admission
Time Frame: 30-days
Incidence of hospital re-admission within 30-days of index surgery
30-days
Mortality
Time Frame: Up to 1-year post-operative
7-day, 30-day, and 1-year mortality.
Up to 1-year post-operative

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

July 1, 2023

Primary Completion (Estimated)

January 1, 2024

Study Completion (Estimated)

June 1, 2024

Study Registration Dates

First Submitted

June 21, 2023

First Submitted That Met QC Criteria

July 19, 2023

First Posted (Actual)

July 27, 2023

Study Record Updates

Last Update Posted (Actual)

July 27, 2023

Last Update Submitted That Met QC Criteria

July 19, 2023

Last Verified

June 1, 2023

More Information

Terms related to this study

Other Study ID Numbers

  • REB23-0043

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Surgery

Clinical Trials on Goal-directed therapy

3
Subscribe